Search research articles
Contact Us
Filters
Showing results (91-100 of 101) with videos related to
Page
of 11
Sort By:
BMC Cancer
|
June 16, 2021
Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer
Jing Yu, Caijin Lin, Jiahui Huang, et al.
Journal of Cancer
|
October 2, 2018
Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study
Wei Wang, Xiaosong Chen, Lin Lin, et al.
Journal of Translational Medicine
|
October 11, 2012
Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer
Yiqing Tang, Li Zhu, Yafen Li, et al.
Cancer Research
|
September 6, 2024
B7-H3-Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
Licui Jiang, Fengtao You, Hai Wu, et al.
Advances in Therapy
|
December 5, 2018
Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study
Hui Xie, Jinping Liu, Shiyou Yu, et al.
Cancers
|
July 9, 2022
The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial
Deyue Liu, Jiayi Wu, Caijin Lin, et al.
The International Journal of Biological Markers
|
November 12, 2014
Outcomes of adjuvant endocrine therapy and hormone receptor status change following neoadjuvant chemotherapy in breast cancer patients
Jia Yi Wu, Wei Guo Chen, Xiao Song Chen, et al.
Medcomm
|
January 20, 2026
Triple HER2 Blockade With Trastuzumab, Pertuzumab, and Pyrotinib Versus Dual HER2 Blockade in the Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Randomized, Phase II Study
Jiahui Huang, Haoyu Wang, Yiwei Tong, et al.
Cancer Research and Treatment
|
February 6, 2020
Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study
Jiayi Wu, Shuning Ding, Lin Lin, et al.
Science China. Life Sciences
|
March 11, 2016
Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells
Fengtao You, Licui Jiang, Bozhen Zhang, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 101) with videos related to
Sort By:
Page
of 11
BMC Cancer
|
June 16, 2021
Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer
Jing Yu, Caijin Lin, Jiahui Huang, et al.
Journal of Cancer
|
October 2, 2018
Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study
Wei Wang, Xiaosong Chen, Lin Lin, et al.
Journal of Translational Medicine
|
October 11, 2012
Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer
Yiqing Tang, Li Zhu, Yafen Li, et al.
Cancer Research
|
September 6, 2024
B7-H3-Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors
Licui Jiang, Fengtao You, Hai Wu, et al.
Advances in Therapy
|
December 5, 2018
Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study
Hui Xie, Jinping Liu, Shiyou Yu, et al.
Cancers
|
July 9, 2022
The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial
Deyue Liu, Jiayi Wu, Caijin Lin, et al.
The International Journal of Biological Markers
|
November 12, 2014
Outcomes of adjuvant endocrine therapy and hormone receptor status change following neoadjuvant chemotherapy in breast cancer patients
Jia Yi Wu, Wei Guo Chen, Xiao Song Chen, et al.
Medcomm
|
January 20, 2026
Triple HER2 Blockade With Trastuzumab, Pertuzumab, and Pyrotinib Versus Dual HER2 Blockade in the Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Randomized, Phase II Study
Jiahui Huang, Haoyu Wang, Yiwei Tong, et al.
Cancer Research and Treatment
|
February 6, 2020
Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study
Jiayi Wu, Shuning Ding, Lin Lin, et al.
Science China. Life Sciences
|
March 11, 2016
Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells
Fengtao You, Licui Jiang, Bozhen Zhang, et al.
Page
of 11